Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study

Table 2 Serum biochemistry profiles

Group	ALT	ALP	Bil	Alb	AFP	Creatinine
	(U/L)	(U/L)	(mg/dL)	(g/dL)	(ng/mL)	(mg/dL)
CTR	31 (18-42) [7/7]	NA	NA	NA	NA	NA
CHB	40 (22-232) [32/46]	96 (63-171) [14/46]	1.4 (0.4-2.2) [5/46]	3.4 (2.9-3.9) [2/46]	NA	1.4 (1.3-1.5) [2/46]
CIR	51 (10-243) [30/47]	286 (75-558) [5/47]	1.9 (0.3-22.4) [19/47]	2.7 (1.5-39.0) [20/47]	6 (2-12) [4/47]	1.4 (0.8-2.8) [17/47]
HCC	74 (28-332) [32/42]	259 (82-648) [25/42]	1.8 (0.3-21.5) [28/42]	3.1 (1.3-35.0) [26/42]	4900 (4-70000) [34/42]	0.9 (0.4-1.3) [23/42]

Data are represented as median (range) [number of subjects included/total number of subjects in subgroup]. CTR: Healthy controls; CHB: Chronic hepatitis-B related liver disease; CIR: Cirrhosis; HCC: Hepatocellular carcinoma; ALT: Alanine transaminase; ALP: Alkaline phosphatase; Bil: Bilirubin; Alb: Albumin; AFP: α-fetoprotein; NA: Unavailable.